Nucresiran
RNA / oligonucleotide
Evidence outlook · registrational
Transthyretin Amyloidosis with Polyneuropathy: registrational readout pending
No completed mid-stage readout is on record. Registrational readout expected around 2027-12-27.
Also in development:Transthyretin Amyloidosis with Cardiomyopathy · Phase 3
Company guidance: data expected by 2030 (Alnylam Pharmaceuticals, 29 Oct 2026). “We continue to expect to launch nucresiran in ATTR-CM by 2030, assuming positive data and regulatory approval.” Source ↗
The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
TRITON-PN NCT07223203 · Transthyretin Amyloidosis with Polyneuropathy Registry: NCT07223203 | 3 | Change from Baseline in the Modified Neuropathy Impairment Score +7 (mNIS+7) Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 9 (Baseline and Month 9) 2027-12-27 | In progress: results expected 27 Dec 2027 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (2)
What this study did
What this study did
Phase 1 (1)
What this study did
Competitive landscape
Other Transthyretin (TTR) drugs
Acoramidis, Eplontersen, Patisiran, Vutrisiran, Inotersen and 3 more. Compare all 9 Transthyretin (TTR) drugs
This mechanism is crowded: 8 other tracked programmes target it, 5 of them ahead of this one.
This drug's own stage for Transthyretin Amyloidosis with Cardiomyopathy: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Nucresiran: this drug | Phase 3 | RNA / oligonucleotide | Transthyretin (TTR) | not yet graded | No reviewed efficacy summary in this indication | |
| Acoramidis (Attruby) | Approved | Small molecule | Transthyretin (TTR) | not yet graded | No reviewed efficacy summary in this indication | |
| Vutrisiran (AMVUTTRA) | Approved | RNA / oligonucleotide | Transthyretin (TTR) | Reliable signal | NCT04153149: Composite of all-cause mortality and recurrent cardiovascular events: overall population HR 0.718 (95% CI 0.555 to 0.929), p=0.0118; vutrisiran monotherapy subgroup HR 0.672 (95% CI 0.487 to 0.929), p=0.0162 | |
| Cliramitug | Phase 3 | Monoclonal antibody | Transthyretin (TTR) | not yet graded | No reviewed efficacy summary in this indication | |
| Coramitug | Phase 3(overall) | Monoclonal antibody | Transthyretin (TTR) | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Eplontersen (Wainua) | Phase 3 | RNA / oligonucleotide | Transthyretin (TTR) | Partial signal | NCT04136171: CARDIO-TTRansform primary composite: rate ratio 0.89 (95% CI 0.73 to 1.09), P=0.28; no significant reduction. missed | |
| Nexiguran Ziclumeran | Phase 3 | Gene therapy / editing | Transthyretin (TTR) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Nucresiran to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.